专利检索 ap:("The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.") AND inv:"Clifton Dalgard" 第 1 页

1.

发明授权
Inhibitors for ERG oncogene positive cancers 有权

公开(公告)号：US09782394B2

公开(公告)日：2017-10-10

申请号：US15125438

申请日：2015-03-12

申请人： The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.

发明人： Clifton Dalgard , Ahmed Mohamed , Meera Srivastava , Shiv Srivastava

IPC分类号： A61K31/44 , A61K31/4402 , C09B29/28 , C09B67/46 , A61K31/135 , A61K31/136 , A61K31/426 , A61K45/06

CPC分类号： A61K31/4402 , A61K31/135 , A61K31/136 , A61K31/426 , A61K45/06 , C09B29/28 , C09B67/009

摘要： Alterations to the ERG gene are some of the most prominent genomic changes associated with many cancers including prostate cancer. Such cancer specific alterations result in the overexpression of wild type ERG protein or an altered ERG protein. The present invention provides selective inhibitors of wild type or an altered ERG protein expression. The ERG inhibitors of the invention, therefore, are therapeutic agents for treating ERG positive cancers.